RxDoctor Payments Data

Jonas Vanags, MD

Neurology · Savannah, GANPI 1245474048

Payments from drug & device makers

$14,881in general payments, 2019–2025

Across 757 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$893
  • EMD Serono, Inc.$807
  • Teva Pharmaceuticals USA, Inc.$598
  • Supernus Pharmaceuticals, Inc.$583
  • Neurelis, Inc.$570
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$14,67699%
  • Education$1881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)98$1,520
Pfizer42$893
EMD Serono, Inc.34$807
Teva Pharmaceuticals USA, Inc.28$598
Supernus Pharmaceuticals, Inc.79$583
Neurelis, Inc.26$570
SK Life Science, Inc.23$569
Novartis26$533
AstraZeneca(2 entities)23$502
UCB, Inc.17$419
Lundbeck LLC17$407
Amgen(2 entities)20$402
Genentech USA, Inc.17$390
Eisai Inc.18$388
Kyowa Kirin, Inc.19$379
Neurocrine Biosciences, Inc.16$365
Biogen17$357
CSL Behring14$346
Argenx US, Inc.9$318
Tanabe Pharma America, Inc.13$289
Acadia Pharmaceuticals Inc14$268
Jazz Pharmaceuticals Inc.11$256
Impel Pharmaceuticals Inc.12$236
Otsuka America Pharmaceutical, Inc.9$187
Lilly USA, LLC11$172
Biohaven Pharmaceutical Holding Company Ltd.7$166
Averitas Pharma Inc.5$160
Grifols USA, LLC7$151
Biohaven Pharmaceuticals, Inc.8$143
Takeda Pharmaceuticals U.S.A., Inc.5$136
Sanofi5$128
Amylyx Pharmaceuticals, Inc.4$125
Johnson & Johnson(2 entities)5$120
Mallinckrodt Hospital Products Inc.5$114
Axsome Therapeutics, Inc.4$114
Amneal Pharmaceuticals LLC5$112
Merz Pharmaceuticals, LLC5$110
MDD US Operations, LLC7$107
Avanir Pharmaceuticals, Inc.6$102
Akcea Therapeutics, Inc.2$94
Scilex Pharmaceuticals Inc.4$85
Acorda Therapeutics, Inc4$81
Banner Life Sciences, LLC4$76
Bristol Myers Squibb5$76
ANI Pharmaceuticals, Inc.3$72
Adamas Pharmaceuticals, Inc.4$72
Upsher-smith Laboratories LLC4$71
TG Therapeutics, Inc.2$57
Catalyst Pharmaceuticals, Inc.2$48
Hospira, Inc.2$48
Sanofi-aventis U.S. LLC2$44
E.r. Squibb & Sons, L.L.C.2$42
Ipsen Biopharmaceuticals, Inc2$37
Avion Pharmaceuticals2$37
Arbor Pharmaceuticals, Inc.2$36
Assertio Therapeutics, Inc.2$30
Medtronic2$29
Mallinckrodt Enterprises LLC2$29
Merz North America, Inc.1$27
Springworks Therapeutics, Inc.1$26

How this compares

$14,881 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$86,431
Medicare patients
370
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab25$641,913
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5015$504,789
PanzygaImmun Glob G(Igg)-Ifas/Glycine12$359,181
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$250,744
Kesimpta PenOfatumumab13$113,320
Aimovig AutoinjectorErenumab-Aooe85$83,651
UbrelvyUbrogepant44$46,331
Nurtec OdtRimegepant Sulfate33$40,368
Emgality PenGalcanezumab-Gnlm35$38,865
QuliptaAtogepant25$33,498
NayzilamMidazolam13$16,251
Ajovy AutoinjectorFremanezumab-Vfrm11$15,078
TopamaxTopiramate11$13,254
Dimethyl Fumarate34$7,788
Lacosamide73$7,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$502$641,91325 claims
CSL BehringPrivigen$346$504,78915 claims
PfizerPanzyga, Nurtec Odt, Lyrica$893$402,66958 claims
Grifols USA, LLCGamunex-C$151$250,74415 claims
AbbVieUbrelvy, Qulipta$1,520$79,83069 claims
UCB, Inc.Nayzilam$419$16,25113 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$112$6,63962 claims
Upsher-smith Laboratories LLCTopiramate$71$98792 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.

Other neurology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →